The FDAnews Webinar Training Pass program offers year-round, unrestricted access to any of the hundreds of webinars listed below. These training programs feature thought leadership and best practices from top consultants, expert speakers and current and former FDA officials. New webinars are offered every month, along with access to the Webinar Training Pass archive.
BUY NOW Single-User 1-Year Unlimited Access $1,362
If you are already a Training Pass member, login below and then scroll down to view the list in date order or narrow your search by keyword or category. Viewing the webinar is easy… simply identify the webinar you want to watch, click on the title and the video will begin. If you would like to view or download the presentation materials separately from the video, click the "Download Presentation" link.
Also available: Take advantage of our multi-user and site licenses of the Webinar Training Pass, so you’ll have the most-informed workforce! Contact Russ Titsch, Business Development Director at russ.titsch@wcgclinical.com or +1 703.538.7651 to receive a custom quote.
Search by keyword, speaker name or just by category (drug, device or clinical) and you'll find all you need.
If you have any questions or are having any problems please give us a call on 703.538.7600 or email customer service.
Webinar Training Pass
Recorded on: Nov. 30, 2022
Description: Take control of compliance and data integrity to accelerate research and development from drug discovery to clinical processes through a unified compliance management solution. Learn how to:
- Unify and connect disparate systems and processes together within your quality and compliance system to mitigate risks and increase efficiencies; and
- Integrate total compliance, quality, and risk management system that will not only replace 10–12-point solutions into one unified solution but also provides a collaborative environment that saves time and speeds up product launches.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Anu Ganguly, Senior Director, Strategic Client Partner, Xybion; and James Castonguay, Assistant Vice President, Product Development, Xybion
Recorded on: Nov. 29, 2022
Description: Effective CAPA implementation needs effective problem communication with team members, clear description of actions and clear goals. Learn how to:
- Communicate corrective actions in a manner to ensure compliance;
- Outline typical CAPA writing problems; and
- Steps to follow to structure effective CAPA’s.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Judith Meritz, Life Sciences Regulatory Consultant, Meritz & Muenz LLP
Recorded on: Nov. 10, 2022
Description: Jessica Ringel sheds light on the changes in user fees, the commitments the FDA’s Center for Devices and Radiological Health (CDRH) has made to the device industry in connection with its performance on marketing applications and related premarket processes — and what that could mean for you — and she’ll discuss what comes next for the unenacted legislation, including:
- How to budget for future marketing applications by understanding the increases in user fees being assessed for device applications;
- CDRH’s timeline commitments so you can better anticipate its marketing application review and the potential effects on timing of new device market launches; and
- When to expect certain guidance documents the FDA has promised to issue over the next few years as part of its MDUFA V commitments, including revisions to the guidance documents on real-world evidence and presubmissions.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jessica Ringel, Partner, King & Spalding
Recorded on: Nov. 9, 2022
Description: Of counsel Paul Gadiock, who was a former associate center director for policy at the FDA’s Center for Devices and Radiological Health, and associate Olivia Cusimano — both with Wilson Sonsini Goodrich & Rosati — clarify the FDA’s current stance on charging for investigational drugs and devices. And they share:
- The factors to consider when deciding whether to seek cost recovery from participants in different clinical trial phases, such as retaining runway revenue and maintaining adequate recruitment;
- Which investigational drug expenses can be recovered without FDA authorization, which can only be recovered with FDA authorization and which cannot be recovered at all; and
- The documentation requirements for sponsors to receive FDA authorization for cost recovery under the agency’s most recent guidance, Charging for Investigational Drugs Under an IND: Questions and Answers.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Paul Gadiock, Of Counsel, Wilson Sonsini Goodrich & Rosati; and Olivia Cusimano, Associate, Wilson Sonsini Goodrich & Rosati
Recorded on: Nov. 8, 2022
Description: Jessica Greenbaum, counsel in King & Spalding’s FDA and Life Sciences practice and former regulatory counsel in the FDA’s Office of Therapeutic Biologics and Biosimilars, walks you through the potential fate of the remaining provisions so you’ll be ready when — or if — the initiatives of most importance to you finally take effect. She provides:
- An overview of the bare-bones user fee package Congress enacted on Sept. 30, 2022;
- A deeper understanding of the key drug- and biologics-related riders that accompanied the original House and Senate bills, including those related to accelerated approval and diversity in clinical trials; and
- Insight into the potential consequences and impacts of these provisions, including how the proposal to amend the first interchangeable exclusivity provisions could facilitate competition.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jessica Greenbaum, Counsel, King & Spalding
Recorded on: Nov. 2, 2022
Description: IQVIA principal consultant and former FDA official Jan Pierre reveals how to build a RWE QMS, including insights on:
- What the regulatory landscape looks like for RWE, particularly the FDA’s Quality Framework to support a new drug or device regulatory filing;
- What programmatic changes you must adopt to set up a RWE program;
- The study feasibility process and its relationship to achieving “evidence quality”, including examples of study feasibility parameters; and
- How to identify new RWE-related roles and responsibilities.
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Jan Pierre, Principal Consultant, IQVIA
Recorded on: Oct. 20, 2022
Description: Arnold & Porter partner Howard Sklamberg — previously a deputy commissioner for global regulatory operations and policy and director of the office of compliance — with senior associate Abraham Gitterman provide a robust overview of the FDA’s proposed rule and recent guidance documents. They’ll cover:
- What you must know about the regulatory and rulemaking process for the FDA’s proposed rule for wholesale drug distributors (WDD) and third-party logistics providers (3PL) licensing;
- Some of the updated and new requirements for WDD and 3PL licensure, including further clarifications for licensure exemptions;
- The potential implications that this law will have in preempting state and/or local laws; and
- How this proposed rule affects other related DSCSA requirements.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Howard Sklamberg, Partner, Arnold & Porter; and Abraham Gitterman, Senior Associate, Arnold & Porter
Recorded on: Oct. 19, 2022
Description: FDA regulatory experts Kristin Zielinski Duggan and Sally Gu dig into the FDA’s guidance around RWE as support for regulatory decision-making and detail key examples of how this evidence has been used. They’ll cover:
- FDA guidance and documentation;
- Practicalities of relying on RWD/RWE; and
- Premarket and Postmarket Obligations.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Kristin Zielinksi Duggan, Partner, Hogan Lovells; and Sally Gu, Associate, Hogan Lovells
Recorded on: Oct. 18, 2022
Description: Three senior directors with decades of experience at the intersection of quality and technology in the life sciences share how an agile QMS can increase study-based audit efficiency within a pharmaceutical organization and/or a CRO’s compliance framework. You’ll discover:
- How to harmonize integration of quality and compliance;
- How to achieve optimal quality management system efficiency;
- How to achieve study-based audit efficiencies within a compliance framework; and
- How to use audits to drive continuous improvements.
Presentation: Download the presentation
Transcript: Download the transcript
Speakers: Amy L. Carlson, CQRM Product Manager, Xybion; Anu Ganguly, Senior Director, Strategic Client Partner, Xybion; and Angie Bixler, CQRM Product Manager, Xybion
Recorded on: Oct. 13, 2022
Description: This webinar breaks out the important requirements needed to assure compliance and to help you verify that the practices in place will meet the rigor of inspection readiness and accurate test reporting. Regulations discussed include:
- Organization and personnel requirements;
- Quality assurance (controlled documents and analytical review and release processes);
- Laboratory equipment (design, qualification, calibration, maintenance and periodic reviews);
- Reagents and standards management practices; and
- Test method development, validation [ICH Q2 R1] and transfer (compendial versus in-house).
Presentation: Download the presentation
Transcript: Download the transcript
Speaker: Tim Fischer, Principal Partner, Great Solutions, LLC